Cholecalciferol loading dose guideline for vitamin D-deficient adults

Lenneke van Groningen 1, Susanne Opdenoordt 1, Adriaan van Sorge 2, Darryl Telting 3, Astrid Giesen 2 and Hans de Boer 1

1 Department of Internal Medicine, Ziekenhuis Rijnstate, 2 Department of Clinical Pharmacology and 3 Department of Clinical Chemistry, Rijnstate Hospital Arnhem, Wagnerlaan 55, 6800 TA Arnhem, The Netherlands

(Correspondence should be addressed to H de Boer; Email: hdeboer@alysis.nl)

Abstract

Introduction: Severe vitamin D deficiency is very common. Evidence-based guidelines for rapid correction with high-dose oral cholecalciferol are not yet available.

Objective: To develop a practical cholecalciferol loading dose regimen.

Materials and methods: A total of 208 vitamin D-deficient subjects (serum 25-hydroxyvitamin D3 (25-OH-D3) level < 50 nmol/l), aged 18–88 years, were treated with solubilized cholecalciferol, 50 000 IU/ml. They received either 25 000 IU every fortnight for 8 weeks (total dose 100 000 IU), 25 000 IU every week for 6 weeks (total dose 150 000 IU), or 25 000 IU every week for 8 weeks (total dose 200 000 IU). Blood samples were collected at baseline and 10 days after the final dose of cholecalciferol.

Results: Most patients were severely vitamin D deficient: 76% had a serum 25-OH-D3 level < 30 nmol/l at baseline. Cholecalciferol in a cumulative dose of 100 000, 150 000, and 200 000 IU increased mean serum 25-OH-D3 level by 29 nmol/l (95% confidence interval (CI): 23–35 nmol/l), 43 nmol/l (95% CI: 36–50 nmol/l), and 69 nmol/l (95% CI: 64–75 nmol/l) respectively. The change in 25-OH-D3 (Δ25-OH-D3) was related to the dose per kilogram body weight (R² = 0.38, P < 0.0001), and is described by the equation: Δ25-OH-D3 = 0.025 × (dose per kg body weight).

Conclusion: The cholecalciferol loading dose required to reach the serum 25-OH-D3 target level of 75 nmol/l can be calculated as follows: dose (IU) = 40 × (75 − serum 25-OH-D3) × body weight.

European Journal of Endocrinology 162 805–811

Introduction

Vitamin D status is related to sunlight exposure and therefore depends on latitude (1). As a result, vitamin D deficiency, defined as a serum 25-hydroxyvitamin D3 (25-OH-D3) level < 50 nmol/l, is very common in Northern Europe. In Germany, for example, 57% of the 18–79-year-old residents are vitamin D deficient, and this is mainly explained by the lack of sufficient sunlight exposure and low dietary vitamin D (2).

Vitamin D deficiency is well known for its musculoskeletal complications in children and adults (1, 3, 4). However, vitamin D receptors are also present on a large variety of extraskeletal cell types, including cardiomyocytes, vascular endothelial cells, neurons, immune cells, and pancreatic β-cells. A rapidly growing body of evidence indicates that vitamin D deficiency may play a role in the development of common cancers, autoimmune diseases, infectious diseases, and cardiovascular diseases (1, 3, 5). Consequently, improvements in the detection and treatment of vitamin D deficiency may have a major health impact.

There is an emerging consensus that serum 25-OH-D3 levels of about 75 nmol/l are optimal for bone health and extraskeletal effects (6, 7). However, there is no consensus on how to achieve this target rapidly. In the USA, ergocalciferol (vitamin D2) is recommended at a dose of 50 000 IU/week for 8 weeks, irrespective of the degree of vitamin D deficiency or body weight (1). In Europe, cholecalciferol (vitamin D3) is mainly used to treat vitamin D deficiency. Usually, this is done with daily supplementation using tablets.

In 2006, the commercially available cholecalciferol tablets (Devaron 400 IU) were suddenly withdrawn from the market in The Netherlands. This forced us to look for alternatives to maintain patient care. We were fortunate to discover a formulation for solubilized cholecalciferol (50 000 IU/ml), which was developed by the Dutch Pharmacists Association (Formularium der Nederlandse Apothekers, FNA) 20 years ago, and which included a guideline for quality control. This formulation is not patented, it is cheap to prepare, and can be used everywhere. Nevertheless, it was hardly prescribed, possibly because of unawareness of its...
were excluded. All patients gave their informed consent.

used medication interfering with vitamin D metabolism

www.eje-online.org

better bioavailability than oily formulations (10, 11).

solubilise changes into a very fine emulsion with

causes micelle formation. After oral administration, the

Cholecalciferol is a fat-soluble vitamin that is solubilized

can be obtained by e-mail, contact: agiesen@alysis.nl.

anise oil, potassium sorbates, polysorbatum 80 (poly-

ferol concentrate in oil, citric acid monohydrate, star

50 000 IU/ml) is a watery mixture made of cholecalci-

The solubilized cholecalciferol developed by the

Subjects and methods

Participants

A total of 208 patients with established vitamin D
deficiency (serum 25-OHD₃ level < 50 nmol/l) were

included. All patients were visitors of the internal

medicine outpatient clinic. They had been tested for

vitamin D deficiency because of unexplained fatigue,
muscle weakness, myalgia, or unexplained hypopho-

sphatemia. Patients with unstable thyroid disorders,
hypoparathyroidism and primary hyperparathyroidism,
evidence of malabsorption, and renal insufficiency

(glomerular filtration rate < 60 ml/min) and those who

used medication interfering with vitamin D metabolism

were excluded. All patients gave their informed consent.

Study design

The solubilized cholecalciferol developed by the

Dutch Pharmacists Association (Cholecalciferol₃FNA

50 000 IU/ml) is a watery mixture made of cholecalci-

ferol concentrate in oil, citric acid monohydrate, star

anise oil, potassium sorbates, polysorbatum 80 (poly-

oxyethylene sorbitan mono-oleate), sugar syrup, and

purified water. The full description of this formulation
can be obtained by e-mail, contact: agiesen@alysis.nl.

Cholecalciferol is a fat-soluble vitamin that is solubilized

by polysorbatum 80, an interface-active substance that

causes micelle formation. After oral administration, the

solubilise changes into a very fine emulsion with

better bioavailability than oily formulations (10, 11).

As dose guidelines were not available, we had to
design a pragmatic dose-escalation study that would be
safe to conduct as part of regular patient care. To
minimize the risk of over supplementation, the first

group of patients (group A, n = 30) was treated with a
low dose: 25 000 IU every fortnight for 8 weeks, i.e. a
total dose of 100 000 IU in 2 months. When the

laboratory results had confirmed that this dose did not
cause hypercalcemia and that the 25-OHD₁ level had

increased by 69 nmol/l or less, it was decided to increase
the loading dose in the next group of patients. They
received 25 000 IU/week for 6 weeks, i.e. a total of
150 000 IU in 2 months (group B, n = 68). Again,
hypercalcemia or potentially toxic vitamin D levels were
not observed. With this regimen, the four biggest
increases in 25-OHD₃ were 160, 130, 108, and
100 nmol/l respectively, and the other responses were
< 100 nmol/l. Complete suppression of serum para-

thyroid hormone (PTH) had not occurred with this dose,
and therefore, it was considered safe to treat the third
group of subjects with 25 000 IU/week for 8 weeks, i.e. a
total dose of 200 000 IU in 2 months (Group C, n = 110).

For the analysis of serum 25-OHD₃, creatinine,
calcium, phosphate, albumin, and PTH, blood samples

were collected at baseline and 10 days after the final
dose of cholecalciferol. This interval was chosen
because it was shown by previous studies that about
10 days are required to convert 90–100% of the
absorbed cholecalciferol into 25-OHD₃ (9). The blood
samples were collected throughout the year, between

Serum 25-OHD₃ concentrations were measured by
RIA (DiaSorin, Stillwater, MN, USA). The detection limit
of this assay is 10 nmol/l, and the intra- and interassay
coefficients of variation are 8.1 and 10.2% respectively.

Serum intact PTH was measured by chemiluminescent
enzyme-labeled immunometric assay (Immulite 2500,
Siemens, Los Angeles, CA, USA).

Statistical analysis

Results are expressed as mean values ± S.D. Data that did
not follow a normal distribution were log-transformed.

Responses to treatment within groups were analyzed by
paired, two-sided t-tests. Between-group differences
were tested by ANOVA and unpaired t-tests. To enable
calculation procedures, 25-OHD₃ levels below the assay’s
detection limit were given a value of 5 nmol/l. Multi-

variate regression analysis was used to identify the
variables that might predict the cholecalciferol loading
dose. Variables included for this analysis were season,
sex, age, height, body weight, body mass index (BMI),
cholecalciferol dose in IU and in IU/kg body weight, and
baseline serum 25-OHD₃. To obtain a simple model that
would be easy to use in daily practice, only those
variables explaining more than 5% of the total variance
were considered to be clinically relevant, and variables
explaining < 5% of the variance were removed. A P value
< 0.05 was considered to be statistically significant.

Results

The baseline characteristics of the patients enrolled in
the study are shown in Table 1 and Fig. 1. Sixty-two
patients had a diagnosis of osteoporosis, and the
remaining subjects had a wide array of diagnoses
Table 1 Baseline characteristics of the study population. Results in mean values ± s.d.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Mean ± s.d.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>55.2 ± 17.2</td>
</tr>
<tr>
<td>Male/female (n)</td>
<td>66/142</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>168 ± 13.7</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>80.5 ± 27.1</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>28.1 ± 7.7</td>
</tr>
<tr>
<td>Serum creatinine (µmol/l)</td>
<td>70.7 ± 28.3</td>
</tr>
<tr>
<td>Serum total calcium (mmol/l)</td>
<td>2.32 ± 0.09</td>
</tr>
<tr>
<td>Serum phosphate (mmol/l)</td>
<td>1.01 ± 0.19</td>
</tr>
<tr>
<td>Serum albumin (g/l)</td>
<td>39.0 ± 3.2</td>
</tr>
<tr>
<td>Serum 25-OHD₃ (nmol/l)</td>
<td>20.5 ± 8.7</td>
</tr>
<tr>
<td>Serum PTH (pmol/l)</td>
<td>5.4 ± 4.6</td>
</tr>
<tr>
<td>Mean dose/kg (IU/kg)</td>
<td>2350 ± 785</td>
</tr>
</tbody>
</table>

commonly seen in a general internal medicine practice of a teaching hospital. The female:male ratio was 2:1. All variables that might affect the magnitude of the loading dose, such as age, body weight, serum 25-OHD₃, and the month of sampling covered a wide range (Fig. 1). A substantial number of patients were obese: 33% had a BMI > 30 kg/m², and 5% were morbidly obese (BMI > 40 kg/m²)

The laboratory results at baseline and 10 days after the final dose of cholecalciferol are summarized in Table 2. The majority of patients were severely vitamin D deficient. Baseline serum 25-OHD₃ level was <10 nmol/l in 12% of the patients, and 76% had levels <30 nmol/l. Cholecalciferol treatment increased the mean 25-OHD₃ level from 20.5 ± 7.8 to 74.8 ± 30.2 nmol/l (P < 0.0001). In total, 76% of the patients achieved a serum 25-OHD₃ level > 50 nmol/l, and 48% of patients achieved a serum 25-OHD₃ level > 75 nmol/l. Hypercalcemia, defined as a serum calcium level > 2.55 mmol/l, was not observed. The mean responses within the groups treated with 100 000, 150 000, or 200 000 IU are shown in Table 2. The individual changes in 25-OHD₃ levels within each group are illustrated in Fig. 2. Baseline 25-OHD₃ levels were similar in the three groups: 19.0 ± 7.4, 20.4 ± 9.7, and 20.7 ± 8.4 nmol/l respectively. The mean 25-OHD₃ increased by 29 nmol/l in group A (95% confidence interval (CI): 23–35 nmol/l, P < 0.0001), by 43 nmol/l in group B (95% CI: 36–50 nmol/l, P < 0.0001), and by 69 nmol/l in group C (95% CI: 64–75 nmol/l, P < 0.0001). The mean rise in serum 25-OHD₃ in group B was greater than that in group A (P < 0.05), and the rise in group C was greater than that in group B (P < 0.0001). The highest post-treatment 25-OHD₃ levels were observed in the subjects receiving 200 000 IU in 2 months. The maximum level was 185 nmol/l (Fig. 2). A statistically significant decrease in serum PTH was observed only in group C (5.5 ± 5.3 – 4.0 ± 2.8, P < 0.01), and complete suppression of serum PTH did not occur (data not shown). Serum creatinine rose from 73.8 ± 41.1 to 80.2 ± 51.2 µmol/l in group B (P < 0.05), and the small increases in groups A and C were statistically not significant.

The range in serum 25-OHD₃ responses was large. This was in part attributed to the wide dose range that varied from 670 to 4348 IU/kg body weight. The variability in response to treatment was comparable for the three groups (Fig. 2). Multivariate regression analysis with all factors except the ‘dose per kg body weight’ showed that the rise in serum 25-OHD₃ was inversely related to body weight and baseline 25-OHD₃, and positively correlated with the total dose (variance of the model: 0.43, P < 0.0001). It was not related to age, sex, body height, BMI, or season in this study population. When the multivariate analysis was repeated, but now with inclusion of the ‘dose per kg body weight’, only two statistically significant determinants remained: baseline serum 25-OHD₃ and the dose per kg body weight (variance of the model: 0.42, P < 0.0001). As the baseline serum 25-OHD₃ explained only 4% of the total variance in this model, it was removed, leaving only the ‘dose per kg body weight’ as a clinically relevant parameter. The increase in 25-OHD₃, expressed as a function of the dose/kg body weight, is shown in Fig. 3. On the left, the complete data set is shown, including the polynomial regression line with its 95% CI in red (R² = 0.40, P < 0.0001). The linear regression line is defined by the equation: Δ25-OHD₃ = −1.15 + 0.024 × (dose per kg body weight), R² = 0.38, P < 0.0001. This line fell well within the 95% CI of the polynomial line.
To obtain a practical instrument, the linear equation was simplified. The intercept had a 95% CI of $K_{11.0-9.4}$, and thus did not differ from zero, which allows elimination from the equation. The 95% CI of slope of the line ranged from $0.020$ to $0.028$. This variability allows a minor deviation to a mean slope value of $0.025$. Both measures resulted in a more simple equation that would be easy to use in general practice:

$$D_{25-OHD_3} = 0.025 \times (\text{dose per kg body weight}).$$

This line also fell within the 95% CI of the polynomial curve (not shown). The dose required for correction of the serum $25-OHD_3$ level can be derived from Fig. 3 on the right. This figure focuses on the clinically relevant range for vitamin D correction, i.e. corrections of up to 100 nmol/l. For example, a patient with a $25-OHD_3$ level of 5 nmol/l will require a rise of 70 nmol/l to reach the target level of 75 nmol/l ($\Delta 25-OHD_3 = 75 - 5 = 70 \text{ nmol/l}$). To achieve this level, a cholecalciferol dose of 3000 IU/kg body weight will be required. The loading dose can also be calculated with the equation: loading dose (IU) $= 40 \times (75 - \text{serum} 250HD_3 \text{ (nmol/l)}) \times (\text{body weight (kg)})$.

It is stressed that this equation should not be used for subjects with body weights $> 125 \text{ kg}$. As shown in Fig. 1, only a few patients had body weights larger than 125 kg.

### Discussion

This study has formulated a loading dose guideline for rapid correction of vitamin D deficiency using solubilized cholecalciferol. The calculation of the dose required to normalize serum $25-OHD_3$ is based on the degree of vitamin D deficiency and body weight. It appears to be a safe procedure. In this study, no toxic effects were observed, hypercalcemia did not develop, vitamin D levels never reached the danger range, and complete suppression of PTH levels was not observed. The sampling was well distributed over all seasons, including summer, which further supports the safety of the proposed regimen. The study included young and elderly subjects, lean and obese, with a variety of underlying diagnoses such as those commonly seen in the outpatient clinic of internal medicine in a general teaching hospital. Therefore, the described approach is applicable in a broad array of subjects; however, it is not valid in the case of malabsorption. Once the target level is reached, a maintenance dose will be required to sustain the serum $25-OHD_3$ level around 75 nmol/l.

### Table 2

<table>
<thead>
<tr>
<th></th>
<th>Before</th>
<th>After</th>
</tr>
</thead>
<tbody>
<tr>
<td>Creatinine (μmol/l)</td>
<td>65.7±14.6</td>
<td>66.2±13.6</td>
</tr>
<tr>
<td>Total calcium (mmol/l)</td>
<td>2.34±0.11</td>
<td>2.33±0.18</td>
</tr>
<tr>
<td>Phosphat (mmol/l)</td>
<td>1.05±0.20</td>
<td>1.13±0.37</td>
</tr>
<tr>
<td>Albumin (g/l)</td>
<td>39.0±3.4</td>
<td>39.7±3.9</td>
</tr>
<tr>
<td>PTH (pmol/l)</td>
<td>4.3±1.5</td>
<td>3.5±1.9</td>
</tr>
<tr>
<td>$25-OHD_3$ (nmol/l)</td>
<td>19.0±7.4</td>
<td>48.3±13.0</td>
</tr>
<tr>
<td>Dose/kg (IU/kg)</td>
<td>1495±378</td>
<td>2028±553</td>
</tr>
<tr>
<td>$\Delta 25-OHD_3$ (nmol/l)</td>
<td>29.3±15.4</td>
<td>43.1±29.1</td>
</tr>
</tbody>
</table>

$\Delta 25-OHD_3$, change in $25-OHD_3$ level. For comparison within groups: *$P<0.05$; †$P<0.01$; ‡$P<0.0001$.

### Figure 2

Changes in serum $25-OHD_3$ in response to the oral administration of solubilized cholecalciferol. Group A: 100 000 IU, group B: 150 000 IU, and group C: 200 000 IU.
The present study does not provide data on this. The optimal maintenance dose for solubilized cholecalciferol remains to be determined, and this is currently the subject of further study.

Until recently, vitamin D supplementation studies were mainly limited to elderly people, particularly those who lived in nursing homes where the prevalence of vitamin D deficiency is 75% or higher. Some studies evaluated the efficacy of high doses at monthly or 3-month intervals, but most studies have used the officially recommended cholecalciferol dose of 600–800 IU/day, or equivalents thereof (12–16). Most studies used predefined fixed doses, irrespective of the degree of vitamin D deficiency and body weight, and assessed the efficacy of the regimen after 4–6 months or longer. These studies were not designed to establish the requirements for a loading dose. A dose of 800 IU/day may help to improve vitamin D status in the long run, but it is not the optimal approach to achieve a rapid correction of severe vitamin D deficiency (16). According to our calculations, a 75-kg patient with a serum 25-OHD₃ level of 5 nmol/l will need a total loading dose of 210 000 IU to raise the serum level to 75 nmol/l. If, for simplicity, 100% absorption is assumed, a daily dose of 800 IU will take 3 months to raise the level to 30 nmol/l, 5.5 months to raise the level to 50 nmol/l, and almost 9 months to reach the target level of 75 nmol/l.

It is well established that the serum 25-OHD₃ levels achieved with a fixed dose of oral cholecalciferol are inversely related to body weight or BMI (17, 18). This is not unexpected since obese subjects have lower baseline 25-OHD₃ levels than the non-obese subjects. Also, the rise in serum 25-OHD₃ will be less in obese subjects because of the larger distribution volume due to the marked increase in body fat. In view of these aspects, we adjusted the loading dose for body weight. Multivariate regression analysis confirmed that the introduction of the factor ‘dose per kg body weight’ removed the relation between the rise in serum 25-OHD₃ and body weight. The study population demonstrated a wide range in body weights, and therefore, the equation is considered to be valid for lean, normal, and obese subjects. For the present, however, we advise against its use in morbidly obese subjects, i.e. subjects with a BMI > 40 kg/m². Experience with this subgroup is still too limited to allow firm conclusions.

Discussions on vitamin D requirements and daily allowances are not new. Over the years, the recommended daily dose for adults has gradually increased from 200 to 800 IU, and recently, doses of 1000 and even 2000 IU/day or higher have been proposed (19, 20). As discussed by Vieth in an excellent review on vitamin D supplementation and safety, many recommendations before 1997 lacked any scientific basis, and the more recent recommendations are often still too low (19). Vitamin D toxicity is often feared for, but usually this fear is unfounded. All published cases of vitamin D toxicity involved intakes of more than 40 000 IU/day for a prolonged period of time, with serum 25-OHD₃ levels exceeding > 250 nmol/l. To achieve these levels, daily doses of 15 000 IU or more for many months are needed. The lowest cumulative dose of cholecalciferol leading to toxic 25-OHD₃ levels was 3 600 000 IU given in 3 weeks (19). The loading doses that we have proposed are 10–20 times less, which is another argument to consider them as safe.

Data derived from a dose-escalation study in healthy men with a mean weight of 85 kg are of interest to compare with those derived from the present method (21). Based on the responses of oral cholecalciferol given in doses of 0, 1000, 5000, or 10 000 IU/day for a period of 20 weeks, it could be calculated that a rise in cholecalciferol intake of about 57 IU/day is needed to establish a 1 nmol/l rise in serum 25-OHD₃. Applied to our population, and given for 8 weeks, a total amount of 57×7×8×50 or 160 000 IU would be required to increase serum 25-OHD₃ by 50 nmol/l in an 85-kg subject. This compares well with the 170 000 IU that are required according to our calculation model. The advantages of our method are that it is applicable to a broad variety of subjects, and that it allows adjustment.
for body weight. The effect of body weight is considerable: a 50 nmol/l rise in a 60-kg subject will require a loading dose of 120 000 IU, whereas a 100-kg subject will require 200 000 IU.

In the present study, cholecalciferol was given in doses of 25 000 IU/week. Higher doses or a higher dose frequency might shorten the treatment period, but it is not exactly known how this will affect the 25-OHD$_3$ response. It has been demonstrated that single doses of 50 000 or 100 000 IU are safe and effective. In non-obese subjects, these doses raised serum 25-OHD$_3$ to peak levels of about 15 and 35 nmol/l within 1–2 weeks respectively (9, 22). The use of these higher doses may alter the vitamin D$_3$ pharmacokinetics to an extent that an adjusted dose calculation might be required. There is evidence that very high doses may saturate hydroxylation reactions, thereby reducing the efficiency to generate 25-OHD$_3$ within a given period of time (23).

Another aspect that is relevant to the assessment of loading doses is the ongoing debate concerning the bioequivalence of ergocalciferol and cholecalciferol (8, 9, 23–27). All studies using single boluses or brief treatment periods with relatively high doses of vitamin D indicate that cholecalciferol is more potent than ergocalciferol in raising serum 25-OHD$_3$. This applies to the oral route as well as to the i.m. route (26). Estimates are that cholecalciferol is 2–3 times more potent than ergocalciferol in raising serum 25-OHD$_3$. This lower potency has been attributed to a shorter half-life as a result of a lower binding affinity to vitamin D-binding protein (24). In contrast to these observations, ergocalciferol was found to be equally effective as cholecalciferol in maintaining serum 25-OHD$_3$ status when treatment was given for a prolonged period of time, e.g. 3 months, and at a much lower dose (25). The magnitude of the dose may be the key to explaining the discrepancy between the studies. As long as this issue is not fully clarified, the recommended dose calculation procedure should only be relied upon to assess the cholecalciferol loading dose.

In conclusion, for rapid correction of vitamin D deficiency, we recommend a cholecalciferol loading dose regimen based on the equation: dose (IU) = 40 × (75 − serum 25-OHD$_3$) × body weight. The equation is based on data derived from subjects weighing 125 kg or less, and thus, it should not be used in subjects with considerable larger body weights. Furthermore, it is important to note that the calculated loading dose should be given in portions of 25 000 IU/week. Higher doses per week or higher dosing frequencies might affect the vitamin D$_3$ pharmacokinetics, and thus require an adjusted dose calculation.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This study did not receive any specific grant from any funding agency in the public, commercial, or not-for-profit sector.

References


Received 23 December 2009
Accepted 3 February 2010